Patents by Inventor Paul Reichert

Paul Reichert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiation Curable Coating Composition
    Publication number: 20080113192
    Abstract: The invention relates to a radiation curable composition including a polyester urethane (meth)acrylate oligomer prepared from ortho-carboxylic polyester polyols, where the composition, after cure, has a secant modulus greater than about 600 MPa and an elongation at break of at least about 10%. The invention also relates to coated optical fibers and optical fiber ribbon including at least one coating derived from this composition, and to a process of making these coated optical fibers.
    Type: Application
    Filed: October 13, 2005
    Publication date: May 15, 2008
    Inventors: Edward Paul Zahora, Anthony Joseph Tortorello, Edward Joseph Murphy, Anthony Fitzroy Toussaint, Timothy Paul Reichert, Kelly An Hawkinson
  • ERK2 CRYSTALS
    Publication number: 20080081360
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Application
    Filed: October 17, 2007
    Publication date: April 3, 2008
    Inventors: Jessie English, Thierry Fischmann, Thomas Hesson, Alan Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Taremi
  • ERK2 crystals
    Patent number: 7312061
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: December 25, 2007
    Assignee: Schering Corporation
    Inventors: Jessie English, Thierry Oliver Fischmann, Thomas Hesson, Alan William Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Shane Taremi
  • Crystalline form of an n231 mutant catalytic domain of ADAM33 and methods of use thereof
    Patent number: 7285408
    Abstract: The present invention discloses purified polypeptides that comprise an active human ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human ADAM33 catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human ADAM33. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human ADAM33 in structure based drug design to identify compounds that can modulate the enzymatic activity of human ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the human ADAMS33 catalytic domain.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: October 23, 2007
    Assignee: Schering Corporation
    Inventors: Peter Orth, Paul Reichert, Vincent S. Madison, Wenyan Wang, Jun Zou
  • ERK2 crystals
    Publication number: 20060088924
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Application
    Filed: September 23, 2005
    Publication date: April 27, 2006
    Inventors: Jessie English, Thierry Fischmann, Thomas Hesson, Alan Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Taremi
  • Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
    Publication number: 20050037383
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Application
    Filed: April 9, 2004
    Publication date: February 17, 2005
    Inventors: Shahriar Taremi, Gaolian Xie, Thomas Hesson, Jose Duca, Corey Strickland, William Windsor, Vincent Madison, Rumin Zhang, Paul Reichert
  • Hepatitis C virus NS3 helicase fragments
    Publication number: 20040253577
    Abstract: This invention provides fragments of HCV NS3 helicase, and crystalline compositions thereof, based on subdomains of HCV helicase protein. The protein fragments are stable, soluble, and structurally sound. They can be expressed at high levels in conventional expressions systems, such as E. coli, to permit efficient, large-scale production for NMR-based screening applications and production of [2H,13C,15N]- and [13C,15N]-labeled polypeptides for structural NMR studies. Helicase fragments of the present invention are useful in the most advanced NMR techniques available, e.g., NMR-based drug discovery techniques such as SAR-by-NMR, in biological assays to discover inhibitors of HCV NS3 helicase, and to evaluate the mechanism of action and substrates for HCV NS3 helicase. Crystals of the present invention are useful for structure-based drug design studies using x-ray crystallographic techniques.
    Type: Application
    Filed: April 3, 2001
    Publication date: December 16, 2004
    Inventors: Patricia C. Weber, Paul Reichert, Vincent S. Madison, Daniel F. Wyss, Nanhua Yao, Dingjiang Liu, Jennifer J. Gesell
  • Crystalline form of the catalytic domain of ADAM33 and methods of use thereof
    Publication number: 20040157309
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of ADAM33. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Application
    Filed: December 19, 2003
    Publication date: August 12, 2004
    Applicant: Schering Corporation
    Inventors: Peter Orth, Paul Reichert, Vincent S. Madison, Wenyan Wang, Jun Zou
  • Beta-secretase crystals and methods for preparing and using the same
    Publication number: 20040014194
    Abstract: The present invention relates to the expression, purification and crystallization of glycosylated &bgr;-secretase protein and a complex thereof. The crystals of the invention are useful, inter alia, for determining the three-dimensional structure of &bgr;-secretase and of other, related proteins.
    Type: Application
    Filed: March 26, 2003
    Publication date: January 22, 2004
    Applicant: Schering Corporation
    Inventors: Brian M. Beyer, Gerald S. Hammond, Paul Reichert, Corey Strickland, Wenyan Wang, Patricia C. Weber, Gwendolyn Tse Wong, Lili Zhang
  • Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
    Patent number: 6524589
    Abstract: The invention relates to the purification and crystallization of hepatitis C virus (HCV) NS3/NS4A polypeptide complex. Also, crystallization conditions for NS3/NS4A are provided. Further, the atomic coordinates for the NS3/NS4A protein are disclosed. Examples of its use for the determination of the three-dimensional atomic structures of HCV NS3/NS4A with substrate(s) or substrate analog(s) or inhibitor complexes are also provided.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: February 25, 2003
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Winifred W. Prosise, Shahriar Shane Taremi, Nanhua Yao, Patricia C. Weber
  • Monomeric lipophilic oligosaccharide antibiotic compositions
    Patent number: 6380172
    Abstract: This invention relates to pharmaceutical composition comprising a lipophilic oligosaccharide antibiotic in a substantially monomeric form.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: April 30, 2002
    Assignee: Schering Corporation
    Inventors: Patricia C. Weber, Ashit Kumar Ganguly, Paul Reichert, Charles W. McNemar, William T. Windsor, Eric W. Kaler
  • Crystalline protein controlled release compositions
    Patent number: 6004549
    Abstract: A pharmaceutical composition comprised of a crystalline protein and polyethylene glycol or vegetable oil and a process for producing the same.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: December 21, 1999
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Alan W. Hruza, Nagamani Nagabushan, Tattanahalli Nagabhushan
  • Crystalline interferon alpha for pulmonary delivery and method for producing the same
    Patent number: 5972331
    Abstract: A method to prepare crystalline interferon alpha suitable for aerosol formulation either for systemic or topical (inhaled) drug delivery. The bioavailable interferon is in the form of crystalline submicrometer particles having a predetermined medium diameter.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: October 26, 1999
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Patricia C. Weber, Rowena F. Choudrie, Bruce O. Stuart, Tattanahalli Nagabhushan, Ashit Ganguly
  • Method for preparing zinc interferon alpha-2 crystals
    Patent number: 5741485
    Abstract: A method for making crystals of zinc interferon alpha-2, and the use thereof in depot formulations, are disclosed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 21, 1998
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
  • Crystalline r-h-GM-CSF and method
    Patent number: 5616555
    Abstract: This invention provides a crystalline form of recombinant human granulocyte-macrophage colony-stimulating factor (r-h-GM-CSF) and methods for making such crystals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 1, 1997
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
  • Method for producing metal-interferon-.alpha. crystals
    Patent number: 5602232
    Abstract: A method for producing a crystalline zinc interferon (IFN) .alpha.-2 comprising forming a soluble solution of IFN .alpha.-2 and a metal acetate salt under condtions wherein supersaturation and metal alpha interferon crystals occur.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: February 11, 1997
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Charles McNemar, Nagamani Nagahhushan, Tattanahalli L. Nagahhushan, Stephen Tindall, Alan Hruza
  • Crystalline interleukin-4
    Patent number: 5597900
    Abstract: A process for crystallizing recombinant human interleukin 4 (rhulL-4) from a solution containing a sulfate or citrate salt is described. The crystalline form is suitable for x-ray diffraction and has wide applications in several pharmaceutical processes including purification, formulation and manufacturing.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: January 28, 1997
    Assignee: Schering Corporation
    Inventors: Gerald Hammond, Hung V. Le, T. L. Nagabhushan, Paul Reichert, Paul P. Trotta
  • Method for preparing interferon alpha-2 crystals
    Patent number: 5460956
    Abstract: A method for making crystals of interferon alpha-2 and the use thereof in depot formulations are disclosed.
    Type: Grant
    Filed: December 1, 1992
    Date of Patent: October 24, 1995
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
  • Metal-interferon-alpha crystals
    Patent number: 5441734
    Abstract: The present invention provides for crystalline zinc-interferon alfa-2 (IFN .alpha.-2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN .alpha.-2, crystalline calcium-IFN .alpha.-2, and crystalline IFN .alpha.-2 having a serum half-life of at least about 12 hours when injected into a primate. The present invention further provides for a method for producing a crystalline IFN .alpha.-2 comprising forming a soluble metal-IFN .alpha.-2 complex, and equilibrating the soluble metal-IFN .alpha.-2 complex in solution with an acetate salt of the metal under conditions that will cause the metal-IFN .alpha.-2 solution to become supersaturated and form crystalline metal-IFN .alpha.-2. The present invention also includes crystalline metal-alfa interferon having monoclinic, plate and needle morphologies.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: August 15, 1995
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Charles McNemar, Nagamani Nagabhushan, Tattanahalli L. Nagabhushan, Stephen Tindall, Alan Hruza
  • Purification of GM-CSF
    Patent number: 5391706
    Abstract: A method of purifying granulocyte-macrophage colony-stimulating factor (GM-CSF), particularly recombinant human GM-CSF, in good yield and with retention of biological activity, comprising sequential anion-exchange, dye-ligand affinity, gel filtration and reversed-phase chromatography is disclosed.
    Type: Grant
    Filed: September 21, 1993
    Date of Patent: February 21, 1995
    Assignee: Schering Plough Corporation
    Inventors: Paul P. Trotta, Gail F. Seelig, Robert A. Kosecki, Paul Reichert